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Abstract
Background: Although antiretroviral therapy (ART) is known to be protective against
HIV-related mortality, the expected magnitude of effect is unclear because existing
estimates of the effect of ART may not directly generalize to recently HIV-diagnosed
persons.
Methods: In this study, we estimated 5-year mortality risks for immediate versus no ART
initiation among patients (n¼ 12 547) in the Centers for AIDS Research Network of
Integrated Clinical Systems (CNICS) using the complement of adjusted Kaplan–Meier
survival functions. We subsequently standardized estimates to persons diagnosed with
HIV in the USA between 2009 and 2011, who were enumerated using national surveil-
lance data.
Results: The 5-year mortality, had all patients in the CNICS immediately initiated ART,
was 10.6% [95% confidence interval (CI): 9.3%, 11.9%] compared with 28.3% (95% CI:
19.1%, 37.5%) had ART initiation been delayed at least 5 years. The 5-year mortality risk
difference due to ART among patients in the CNICS was 17.7% (95% CI: 27.0%,
8.4%). Based on methods for generalizing an estimate from a study sample to a differ-
ent target population, the expected risk difference due to ART initiation among recently
HIV-diagnosed persons in the USA was 19.1% (95% CI: 30.5%, 7.8%).
Conclusions: Immediate ART initiation substantially lowers mortality among persons in
the CNICS and this benefit is expected to be similar among persons recently diagnosed
with HIV in the USA. We demonstrate a method by which concerns about generalizability
can be addressed and evaluated quantitatively.
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Introduction
There is no question that effective combination antiretro-
viral therapy (ART) dramatically improves health and sur-
vival among HIV-infected persons and reduces transmission
to susceptible sexual partners.1–5 However, existing esti-
mates of the effect of ART may not directly generalize to
recently HIV-diagnosed persons. Lack of generalizability
has long been recognized as a limitation of clinical trials6,7
but, until recently,8 it has received less attention in the
context of observational studies and has seldom been
quantified.9
The objective of this analysis was to estimate the antici-
pated absolute reduction in all-cause mortality across 5
years of follow-up if all persons recently HIV-diagnosed in
the USA from 2009 to 2011 (the target population) had
been prescribed ART immediately after diagnosis versus if
treatment had been delayed. Given new treatment guide-
lines that suggest immediate ART initiation and public
health efforts to link newly diagnosed persons to care and
treatment immediately following diagnosis, curves describ-
ing the cumulative incidence of mortality associated with
delays in ART initiation that have been generalized to the
characteristics of persons recently diagnosed with HIV
may be particularly compelling to motivate future newly
HIV-diagnosed persons to engage in HIV care and treat-
ment. Because data on the effect of ART in the target
population are not available, we generalized data from
a study sample that was not strictly representative of the
target population; our approach is applicable to other
research questions.
Informally, generalizability problems arise when the
effect of a treatment is heterogeneous across patient sub-
groups and the study sample is not representative of the
target population to whom we would like to apply its
results.10,11 Estimates of the magnitude of the survival bene-
fit due to ART vary across the clinical cohorts and sub-
groups defined by patient demographics and clinical
characteristics.1,12 Furthermore, none of the clinical cohorts
in which the effect of ART has been estimated is representa-
tive of persons recently diagnosed with HIV in the USA.1,12
The Multicenter AIDS Cohort Study and Women’s
Interagency HIV Study (MACS/WIHS) are long-standing
US-based interval cohorts of gay men and women at high
risk for HIV infection, respectively; the hazard ratio for
AIDS or death due to ART in the MACS/WIHS was 0.54
(95% CI: 0.38, 0.78).13 The HIV-CAUSAL Collaboration is
a predominantly European cohort; the hazard ratio for
death due to ART was 0.48 (95% CI: 0.41, 0.57) overall.
Among the 3730 US veterans included in the HIV-CAUSAL
Collaboration, the hazard ratio was 0.62 (95% CI: 0.48,
0.82).1 In the Swiss HIV Cohort Study, whose patients also
contributed person-time to the HIV-CAUSAL analysis, the
hazard ratio for AIDS or death was 0.14 (95% CI: 0.07,
0.29).12 To our knowledge, no other studies of the effect of
ART on mortality have included patients receiving care in
the USA in the study sample, and no study has included per-
sons with AIDS diagnoses at baseline, despite the reality
that 26% of persons newly diagnosed with HIV receive an
AIDS diagnosis either concurrently, or within 3 months of
their HIV diagnosis.14
To obtain an estimate of the effect of ART that was
generalizable to the target population, we first described
the effect of ART on survival in the Centers for AIDS
Research Network of Integrated Clinical Systems (CNICS)
clinical cohort. We then described subgroup effects in the
CNICS and reweighted patients in the CNICS to obtain an
Key Messages
• Existing estimates of the effect of antiretroviral therapy on survival may not generalize directly to persons newly diag-
nosed with HIV in the USA between 2009 and 2011. Concerns about the generalizability of an estimate should be
addressed whenever the study sample is not representative of the target population and the effect of interest is heter-
ogeneous across subgroups.
• With additional information about the distribution of baseline covariates for the target population, generalizability can
be quantitatively assessed through the use of inverse probability weights.
• Immediate initiation of antiretroviral therapy following engagement in care among HIV infected adults in the Center
for AIDS Research Network of Integrated Clinical Systems cohort was associated with a risk of mortality that was
18% lower after 5 years; immediate initiation of antiretroviral therapy was expected to be associated with a 5-year
risk of mortality that was 19% lower among persons diagnosed with HIV in the USA from 2009 to 2011.
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estimate of the average effect of ART generalized to the
target population. This approach to addressing the general-
izability of an estimate allows for a quantitative assessment
of the impact that a non-representative study sample may
have on inference for a specific target population.
Methods
Study population
CNICS is an open clinical cohort of HIV-infected patients,
18 years of age, who have attended at least two HIV pri-
mary care visits at any of eight CNICS sites after 1 January
1995 (or the site-specific CNICS inception date). Patient
demographics, HIV-related diagnoses, laboratory measure-
ments and medications are abstracted from point-of-care
electronic medical records. Mortality information is ob-
tained from clinic sources, death certificates and the Social
Security Death Index, which is queried regularly by CNICS
sites.15 Institutional review boards at each site approved
participation in CNICS, and this analysis of de-identified
data was determined not to constitute human subjects re-
search by the institutional review board of the University
of North Carolina at Chapel Hill.
The study population for this analysis included ART-
naı¨ve patients who enrolled in CNICS and had both CD4
cell count (cells/mm3) and HIV-1 RNA viral plasma con-
centration (viral load, log10 copies/ml) measured at least
once between 1 January 1998 (assumed to approximately
represent the start of the modern ART era) and 30
December 2011 (the last full year for which complete mor-
tality data were available). ART initiation was defined as
having three or more antiretroviral medications prescribed
on the same day, each for at least 30 days. Exclusion crite-
ria included evidence of previous exposure to any anti-
retroviral medication (i.e. mono- or dual therapy or having
an undetectable viral load). Of 12 995 ART-naı¨ve patients
who enrolled in CNICS, 448 (3%) were excluded because
they were missing race/ethnicity (n¼ 113) or transmission
risk category (n¼ 349). The final study population
included 12 547 patients.
Target population
Our aim was to generalize the estimate of the impact
of ART initiation on survival in CNICS to all persons diag-
nosed with HIV infection in the USA from 2009 to 2011.
The number of HIV-diagnosed persons in categories
defined by race/ethnicity, sex, age group, transmission risk
and AIDS diagnosis within 3 months of HIV diagnosis,
was provided by the Centers for Disease Control and
Prevention from national HIV surveillance data and
accounts for delays in reporting new infections.16
Statistical analysis
Let Ti be a random variable denoting survival time in days
from CNICS enrolment to death from any cause. Let Oi be
a random variable denoting time in days from CNICS
enrolment to administrative censoring on 31 December
2011 (patients from one site were administratively
censored on 15 September 2010), at 5 years of follow-up
(to maintain adequately sized risk sets), or at loss to
follow-up (defined as having no contact with the CNICS
clinic, including therapy initiation or laboratory tests, over
a 12-month period). Then let Ti ¼ min Ti;Oið Þ and let the
indicator D denote an observed death, Ti ¼ Ti.
We pooled time into months to adjust for confounding
and possibly differential loss to clinic. Let: Ak be an indica-
tor of having initiated treatment by month k; j denote
the number of completed months since the start of follow-
up; A k1ð Þ denote the history of exposure through month
k 1; and A 1ð Þ ¼ 0 by definition. To mimic an intent-to-
treat analysis, once patients initiated ART, they were
assumed to remain on treatment for the rest of their time
on study.
We estimated exposure effects based on contrasts in
mortality under the interventions ‘initiate ART immedi-
ately’ versus ‘delay ART initiation for at least 5 years
following engagement in care’. That is, we were interested
in contrasts of P Ta¼1 < t
 
and P Ta¼0 < t
 
, where super-
scripts on T denote the potential value of T under exposure
a. In the CNICS, immediate ART initiation was operation-
alized as initiating ART within the first month following
enrolment in the CNICS, which occurs at the second clinic
visit. ‘Immediate’ ART initiation was thus consistent with
routine clinical care (in which physicians would typically
gather information and laboratory measurements on a
patient before initiating them on ART). However, we did
not explicitly build a grace period in our analysis (for ex-
ample, see Cain et al. 2010).17 ‘Immediate’ ART initiation
in the target population is assumed to mean ART initiation
within a similarly short window (i.e. 1 month). Thus,
inherent in our presentation of the counterfactual cumula-
tive incidence cure for immediately treated persons in the
target population is the assumption that following
diagnosis, a person would enter care and start ART within
1 month. We estimated mortality risks, risk differences and
risk ratios using the complement of inverse probability
weighted Kaplan–Meier survival functions.18 For the sake
of completion and comparability with previously published
estimates, we calculated the relative hazard of mortality
associated with ART use using an inverse probability
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weighted marginal structural Cox proportional hazards
model with Efron’s approximation for tied death times.19
We checked for violations of the proportional hazards as-
sumption by checking the statistical significance of an
interaction term between ART initiation and time. We a
priori set alpha¼ 0.1 for this test.
We controlled for confounding and potentially inform-
ative loss-to-clinic in our estimates of effect in the CNICS
with weights that are the product of: (i) stabilized inverse
probability of treatment weights;20,21; and (ii) stabilized in-
verse probability of censoring weights.22 We standardized es-
timates to the target population by applying weights that are
the product of the previous two weights and scaled inverse
probability of sampling weights.9,10
Let Lk be the history of measured time-varying con-
founders through month k, and V be the vector of time-
fixed confounders measured at baseline. Finally, let Ck be
an indicator of censoring in month k and C 1ð Þ ¼ 0 by def-
inition. Inverse probability of treatment weights were then
defined:
wAj ¼
Yj
k¼0f AkjA k1ð Þ;Ck ¼ 0
 
Yj
k¼0f AkjA k1ð Þ;Lk;V;Ck ¼ 0
 
where f AkjA k1ð Þ;Lk;V;Ck ¼ 0
 
is, by definition the con-
ditional probability mass function f
AkjA k1ð Þ;Lk;V;Ck¼0ð Þ
akja k1ð Þ; lk; v; ck ¼ 0
 
with ak; a k1ð Þ; lk; v
 
evaluated at
the random argument Ak;A k1ð Þ;Lk;V
 
. Similarly, inverse
probability of censoring weights were defined:
wCj ¼
Yj
k¼0f Ck ¼ 0jC k1ð Þ ¼ 0;A k1ð Þ
 
Yj
k¼0f Ck ¼ 0jC k1ð Þ ¼ 0;A k1ð Þ;Lk;V
  ; Cj ¼ 0
0; Cj ¼ 1
8>><
>>:
We estimated treatment and censoring weights using
pooled logistic models.
Time-fixed covariates included in the models for the
denominator of the treatment and censoring weights (the
vector V) were: race/ethnicity; sex; age; calendar year; CD4
cell count and viral load most proximate to CNICS enroll-
ment, measured up to 6 months before CNICS enrolment;
previous AIDS diagnosis; history of injection drug use (IDU);
history of male-to-male sexual contact (MSM); and study
site. We combined race and ethnicity into one variable, clas-
sifying patients as Hispanic or Latino if indicated, regardless
of race. Non-Hispanic patients were classified as Black,
White or other race.
Time-varying covariates included in the models for the
denominator of the treatment and censoring weights (the
vector L) were: CD4 cell count, detectable viral load, AIDS
diagnosis,23,24 hepatitis C virus infection and interactions
between CD4 cell count and detectable viral load. Time-
varying covariates were updated whenever a patient was
seen, with intervals determined by medical providers and
by patients’ care-seeking behaviour [median number of
months between measurements¼ 3, interquartile range
(IQR): 2, 4]. Laboratory values were carried forward in
time from the most recent observed value until new values
were reported. All continuous variables were modelled
using restricted quadratic splines with knots at the 5th,
35th, 65th and 95th percentiles.25
When generalizability assumptions are met, inverse
probability of sampling weights re-weight the study sample
to have the same distribution of effect-measure modifiers
as the target population. The inverse probability of sam-
pling weights were defined:
wS ¼
P S ¼ 1ð Þ
P S ¼ 1jGð Þ ; S ¼ 1
0; S ¼ 0
8><
>:
where S is an indicator of inclusion in the CNICS study
sample and G is a vector of time-fixed covariates measured
in both the study sample and the target population. The
covariates in G should include all covariates that: (i) pre-
dict membership in the study sample; and (ii) modify the
effect of interest. The vector of covariates, G, included
race/ethnicity, sex, age group and indicators for MSM,
IDU and AIDS diagnosis at baseline. We additionally
included all second-order interactions between these cova-
riates. CD4 cell count and HIV RNA viral load were ex-
pected a priori to be strong modifiers of the effect of ART
on mortality. However, not all HIV-infected persons have
laboratory tests drawn immediately proximate to their
diagnosis, and not all states currently collect prognostic la-
boratory results as part of their HIV surveillance. Because
we did not have CD4 cell count and viral load measured
on persons in the target population, our main analysis
assumed that the distribution of these two variables match
their distribution in the CNICS sample at baseline. In a
sensitivity analysis, we imputed CD4 cell count and viral
load values for members of the target population under
varying assumptions about how much the true distribution
of these variables in the target population differed from the
CNICS sample. We estimated the inverse probability of
sampling weights using logistic regression on combined
data from the CNICS and the target population. In the
model for sampling weights, we assumed that the specific
set of individuals diagnosed with HIV in the USA between
2009 and 2011, and reported to the CDC, represented one
possible random realization of the target population,
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arising from a super-population of all persons who could
have been diagnosed with HIV in the USA in that time
period. To account for this in our analysis, we weighted
persons in the target population by 1= m=ðN  nÞ½ , where
n is the size of the study sample, m is the size of our target
population and N is the size of the hypothetical super-
population, which is arbitrarily large.26 We set N to be 1.1
million; the choice of N did not influence our results.
Persons in the CNICS received a weight of 1.
When the inverse probability weights for the final struc-
tural model exceeded 40, we explored the potential influ-
ence of large weights on our estimates by modifying the
functional form of covariates in our weight models (e.g.
using quadratic or cubic functions instead of splines) and
by truncating (e.g. interval censoring or winsorizing)
weights at the 0.1st and 99.9th percentile of the distribu-
tion of the weights, and observing the change in the final
estimates.
Finally, to check for the existence of effect measure
modification (a prerequisite for a lack of generalizability),
we examined subgroup-specific effects of ART on mortal-
ity by stratifying the entire analysis according each of the
covariates a priori expected to be associated with the out-
come (those listed as being included in the vector G above,
as well as CD4 cell count and viral load at baseline).
We calculated 95% confidence intervals (CI) using a
standard error estimated by the standard deviation from
200 non-parametric bootstrap random samples drawn
from the study sample and the target population with re-
placement.27 All analyses were carried out using SAS 9.3
(Cary, NC).
Results
Overall, 12 457 patients in the CNICS met the inclusion
criteria; most were male and of White race (Table 1). The
median age at CNICS initiation was 38 years. The median
CD4 cell count and viral load were 304 cells/ll and 46 276
copies/ml, respectively. Nearly one-fifth of CNICS patients
had a history of an AIDS-defining illness at enrolment
(18.7%). Injection drug use (18.7%) and hepatitis C virus
co-infection were also common (14.0%).
Patients were followed for a median of 32 months
[IQR: 17, 60]. During 437 892 person-months of follow-
up, 8703 patients (69%) initiated ART, 5390 patients
(43%) were lost to clinic and 918 patients died. Overall,
5-year mortality in the cohort was 11.3% (95% CI:
10.5%, 12.0%).
The median number of months to ART initiation was 4
(IQR: 1, 16). Strong predictors of ART initiation included
transmission risk factor (IDU, MSM), calendar time of
CNICS enrolment, race/ethnicity, CD4 cell count at
baseline, hepatitis C infection, AIDS diagnosis and time on
study. Strong predictors of loss to clinic included ART ini-
tiation, male sex, MSM transmission risk, calendar time of
CNICS enrolment, CD4 cell count (at baseline and time-
updated), hepatitis C infection, AIDS diagnosis, detectable
viral load and time on study. All covariates listed in the
Methods section were used to estimate treatment and cen-
soring weights regardless of their predictive ability.
Treatment and censoring weights had a mean of 0.98
(range: 0.06, 144.11) and 1.00 (range: 0.32, 12.27), re-
spectively. Using different functional forms of covariates
and truncating weights at 0.1st and 99.9th percentiles
(0.04 and 18.66, respectively) yielded similar results for
the effect of ART on survival.
Figure 1 shows curves for the cumulative incidence of
death over 5 years of follow-up for the CNICS cohort and
Table 1. Characteristics of persons enrolled in the Center for
AIDS Research Network of Integrated Clinical Systems
(CNICS) during 1998–2012, and persons diagnosed with HIV
in the USA during 2009–11
CNICS study
sample at
enrolment
Recently
HIV-diagnosed
persons in the
USA, 2009–11
Total N 12 457 12 8945
Sex
Male 10 265 (82) 100 819 (78)
Female 2282 (18) 28 126 (22)
Age
Median age (IQR) 38 (31, 45)
18–24 years 980 (8) 25 535 (20)
25–34 years 3731 (30) 35 625 (28)
35–44 years 4766 (38) 31 153 (24)
45–54 years 2471 (20) 25 030 (19)
 55 years 599 (5) 11 602 (9)
Race/ethnicity
White 5539 (44) 36 635 (28)
Black 4789 (38) 60 516 (47)
Hispanic 1635 (13) 26 079 (20)
Other 584 (5) 5715 (4)
History of AIDS at baseline 2343 (19) 32 896 (26)
HIV risk category
History of injection drug use only 1440 (12) 6324 (5)
Male-to-male sexual contact only 6606 (53) 77 802 (60)
Injection drug use and
male-to-male sexual contact
903 (7) 4105 (3)
CD4 cell count
Median CD4 cell count (IQR) 304 (111, 488)
 200 cells/ll 4481 (36)
201–350 cells/ll 2650 (21)
351–500 cells/ll 2432 (19)
>500 cells/ll 2984 (24)
Median log10 virus copies/ml 4.7 (4.1, 5.2)
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target population if ART initiation were immediate versus
delayed. In the CNICS cohort, the adjusted risk difference
(RD) in mortality due to ART was 17.7% (95% CI:
27.0%, 8.4%; Table 3). The hazard ratio (HR) was
0.33 (95% CI: 0.25, 0.43). The proportional hazards as-
sumption appeared reasonable (P-value for interaction be-
tween ART initiation and time¼ 0.6). The effect of ART on
survival varied across subgroups of patients, although most
subgroup effects were not statistically significantly different.
RD due to ART use was 14.4% (95% CI: 23.2%,
5.7%) among patients with no reported IDU, compared
with 18.1% (95% CI: 31.8%, 4.4%) among patients
with a history of IDU. ART was strongly protective against
5-year mortality for patients with lower CD4 cell counts at
baseline and less protective as baseline CD4 increased
[RD¼29.3% (95% CI: 43.4%, 15.2%) for those with
baseline CD4 200 cells/mm3 versus RD¼2.5% (95%
CI: 6.0%, 1.0%) for those with baseline CD4> 500 cells/
mm3]. ART was also more strongly protective for patients
with a previous AIDS diagnosis [RD¼ 22.8% (95% CI:
38.3%, 7.3%)] than for those with no previous AIDS
diagnosis [RD¼13.4% (95% CI: 21.3%, 5.5%)].
Finally, among White patients, the RD for AIDS initiation
was 17.3% (95% CI: 28.9%, 5.8%), compared with
11.3% (95% CI: 20.4%, 2.2%) among Black patients
and 10.1% (95% CI: 21.8%, 1.6%) among Hispanic or
Latino patients (Table 2).
Compared with CNICS patients, more people in the tar-
get population were women, Hispanic or Latino, or Black.
The target population had more younger and older people
compared with the age distribution of CNICS patients at
enrolment. More CNICS patients were diagnosed with
AIDS at baseline and fewer had a history of IDU (Table 1).
All covariates were strong predictors of inclusion in the
CNICS. Inverse probability of sampling weights had a
mean of 0.98 (range: 0.17, 14.36).
The estimated RD due to immediate versus delayed
ART initiation that we would have expected among re-
cently HIV-diagnosed persons in the USA was 19.1%
(95% CI: 30.5%, 7.8%) and the HR was 0.32 (95%
CI: 0.23, 0.45) (Table 3). These estimates both assume that
the distributions of CD4 cell count and viral load in the
target population are the same as the distributions of these
variables in the study sample. If, instead, the target popula-
tion were substantially healthier at HIV diagnosis than the
CNICS patients at entry to care (i.e. if the average CD4
cell count in the target population was 200 cells/ll higher
and, among people with ‘high’ viral loads, the viral load
was on average 10 000 copies/ml lower in the target popu-
lation than in the CNICS patients), the HR for the effect of
immediate versus delayed ART initiation among recently
HIV-diagnosed persons in the USA would have been 0.45
(95% CI: 0.28, 0.71). Other scenarios are presented in
Table 4.
Discussion
ART initiation substantxially decreased mortality over 5
years of follow-up among patients in the CNICS. The ef-
fect of ART on mortality was heterogeneous across sub-
groups of patients defined by patient characteristics that
were also predictors of inclusion in the CNICS. Despite the
effect heterogeneity and differences between the study sam-
ple and the target population, the expected magnitude of
the survival benefits of ART among recently HIV-diag-
nosed persons in the USA were similar to those seen in the
CNICS.
The HR for death due to ART estimated in the CNICS
(HR¼ 0.33, 95% CI: 0.25, 0.43) was higher than the HR
for AIDS or death in the Swiss HIV Cohort Study
(HR¼ 0.14, 95% CI: 0.07, 0.29)12 but lower than the HR
for AIDS or death in the MACS/WIHS (HR¼ 0.54, 95%
CI: 0.38, 0.78)13 and lower than the HR for death in the
HIV-CAUSAL Collaboration (HR¼ 0.48, 95% CI: 0.41,
0.57).1 Aside from differences in the source populations
Figure 1. 5-year all-cause mortality under two potential interventions:
always treat versus never treat with three or more antiretroviral medica-
tions (ART) among: (i) persons enrolled in the Center for AIDS Research
Network of Integrated Clinical Systems (CNICS) during 1998–2012; and
(ii) persons diagnosed with HIV in the United States during 2009–11. All
estimates were adjusted for: race/ethnicity; sex; age at engagement in
care; calendar year of engagement in care; CD4 cell count and viral load
most proximate to CNICS enrolment; history of injection drug use; his-
tory of male-to-male sexual contact; study site; and time-varying CD4
cell count, viral load, AIDS diagnosis and hepatitis C virus infection.
Estimates for persons newly diagnosed with HIV in the USA were fur-
ther standardized to the distribution of sex, age group, race/ethnicity,
male-to-male sexual contact, injection drug use and AIDS at baseline in
the target populationdx, diagnosis.
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that contributed to each of these studies, differences in in-
clusion/exclusion criteria and differences in end points
(AIDS or death versus death only), these HRs are difficult
to compare because the period of follow-up is different for
each study, and thus any violations of the proportional
hazards assumption will result in a time-averaged sum-
mary HR that may be dependent on the length of follow-
up.28 We have improved on previous studies estimating the
effect of ART by presenting cumulative incidence curves
and RDs, in addition to HRs, which are arguably more
useful to policy makers for planning.29,30 Furthermore, we
(and the most recent study)1 estimated the effect of ART
on death alone, as opposed to the effect of ART on time to
AIDS or death. In the ART era, the risk of mortality fol-
lowing AIDS diagnosis is significantly reduced,31 making
death a more relevant clinical outcome. We excluded pa-
tients who were not ART naı¨ve, consistent with current
treatment standards.32 Finally, we included people with an
AIDS diagnosis at baseline, in line with the reality that
many patients are diagnosed with AIDS and HIV almost
concurrently and will not have the opportunity to start
ART before they are diagnosed with AIDS.14
For our estimate of the effect of ART on mortality in
the CNICS we assume no unmeasured confounding, posi-
tivity, treatment variation irrelevance or measurement
error, and correct specification of our models for ART
Table 2. Modification of the effect of three or more antiretroviral medications (ART) on all-cause mortality for 12 547 HIV-positive
patients receiving care at CNICS sites, 1998–2011
ART-exposed,
5-year mortality
risk (%)
ART-unexposed,
5-year mortality
risk (%)
Risk difference, %,
(95% confidence
interval)
Risk ratio
(95% confidence
interval)
Hazard ratio
(95% confidence
interval)
Overall 10.6 (9.3, 11.9) 28.3 (19.1, 37.5) 17.7 (27.0, 8.4) 0.37 (0.26, 0.53) 0.33 (0.25, 0.43)
Sex
Male 10.1 (8.7, 11.5) 20.6 (15.2, 26.0) 10.5 (16.1, 4.8) 0.49 (0.36, 0.67) 0.35 (0.27, 0.45)
Female 11.8 (9.7, 14.0) 29.1 (13.1, 45.1) 17.3 (33.5, 1.1) 0.41 (0.23, 0.71) 0.41 (0.26, 0.64)
Age at CNICS start
18–24 years 2.6 (0.7, 4.5) 1.5 (0.0, 9.4) 1.2 (7.0, 9.4) 1.79 (0.27, 12.03) 1.77 (0.00, 1140.12)
25–34 years 6.7 (5.3, 8.2) 22.1 (10.2, 34.0) 15.3 (27.4, 3.3) 0.31 (0.16, 0.58) 0.38 (0.21, 0.66)
35–44 years 10.9 (8.5, 13.2) 18.1 (12.4, 23.8) 7.2 (13.2, 1.2) 0.60 (0.41, 0.87) 0.43 (0.32, 0.57)
45–54 years 15.6 (12.3, 19.0) 44.7 (25.1, 64.2) 29.0 (48.8, 9.2) 0.35 (0.21, 0.59) 0.24 (0.16, 0.37)
 55 years 12.2 (15.1, 27.3) 33.5 (17.2, 49.8) 12.3 (30.0, 5.4) 0.63 (0.35, 1.14) 0.38 (0.18, 0.78)
Race/ethnicity
White 8.2 (6.6, 9.8) 25.5 (14.2, 36.9) 17.3 (28.9, 5.8) 0.32 (0.19, 0.53) 0.26 (0.18, 0.38)
Black 14.4 (11.9, 16.9) 25.7 (16.7, 34.6) 11.3 (20.4, 2.2) 0.56 (0.38, 0.82) 0.44 (0.33, 0.58)
Hispanic 6.1 (4.3, 7.9) 16.2 (4.5, 27.7) 10.1 (21.8, 1.6) 0.38 (0.15, 0.92) 0.37 (0.19, 0.72)
Other 11.5 (4.9, 18.1) 22.9 (1.7, 44.1) 11.4 (33.8, 10.9) 0.50 (0.15, 1.62) 0.74 (0.35, 1.57)
Baseline CD4 count
 200 cells/mm3 17.2 (15.6, 18.9) 46.5 (32.7, 60.4) 29.3 (43.4, 15.2) 0.37 (0.27, 0.52) 0.26 (0.21, 0.33)
201–350 cells/mm3 7.6 (5.6, 9.5) 17.7 (5.1, 30.2) 10.1 (22.8, 2.5) 0.43 (0.21, 0.89) 0.42 (0.26, 0.68)
351–500 cells/mm3 5.5 (2.0, 6.8) 12.6 (0.5, 24.7) 7.1 (19.4, 5.1) 0.44 (0.14, 1.32) 0.51 (0.26, 0.99)
> 500 cells/mm3 4.4 (2.0, 6.8) 6.9 (4.6, 9.2) 2.5 (6.0, 1.0) 0.64 (0.32, 1.28) 0.71 (0.37, 1.37)
Baseline viral load
< 10 000 copies/ml 5.2 (3.2, 7.2) 10.6 (5.5, 15.7) 5.4 (10.8, 0.1) 0.49 (0.26, 0.90) 0.55 (0.31, 0.98)
10 000–99 999 copies/ml 9.6 (7.8, 11.4) 23.7 (12.2, 35.3) 14.1 (26.2, 2.1) 0.40 (0.22, 0.73) 0.50 (0.35, 0.72)
 100 000 copies/ml 13.8 (12.1, 15.6) 42.5 (26.1, 58.9) 28.7 (45.3, 12.1) 0.35 (0.21, 0.51) 0.20 (0.15, 0.26)
AIDS at baseline
Yes 20.7 (17.9, 23.5) 47.5 (27.9, 59.1) 22.8 (38.3, 7.3) 0.48 (0.32, 0.70) 0.39 (0.30, 0.54)
No 7.6 (6.4, 8.7) 20.9 (13.2, 28.7) 13.4 (21.3, 5.5) 0.36 (0.24, 0.54) 0.28 (0.20, 0.40)
Injection drug use
Yes 20.4 (15.6, 25.2) 38.5 (25.4, 51.6) 18.1 (31.8, 4.4) 0.53 (0.35, 0.81) 0.49 (0.34, 0.72)
No 7.8 (7.0, 8.7) 22.3 (13.7, 30.9) 14.4 (23.2, 5.7) 0.35 (0.23, 0.53) 0.30 (0.23, 0.40)
MSM
Yes 7.0 (5.6, 8.4) 15.0 (9.3, 20.7) 8.0 (13.9, 2.0) 0.47 (0.30, 0.72) 0.32 (0.23, 0.45)
No 15.1 (12.7, 17.4) 32.1 (22.1, 42.1) 17.1 (27.4, 6.7) 0.47 (0.33, 0.66) 0.39 (0.29, 0.51)
All estimates were adjusted for: race/ethnicity; sex; age at engagement in care; calendar year of engagement in care; CD4 cell count and viral load most
proximate to CNICS enrolment; history of injection drug use; history of male-to-male sexual contact; study site; and time-varying CD4 cell count, viral load,
AIDS diagnosis and hepatitis C virus infection.
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initiation and loss to clinic. As with all observational stud-
ies, we cannot exclude the possibility of unmeasured con-
founding, but we have adjusted for what we believe to be
the strongest confounders of the effect of ART on mortal-
ity, and our adjustment set includes all strong confounders
that have been included in other studies of the effect of
ART. We had sufficient positivity for our set of confound-
ers, as evidenced by the fact that our weights were gener-
ally well behaved, and which we verified by inspection of
the data. Although ART regimens have changed from
1998 to 2011, we chose to start follow-up in 1998 because
it marked the beginning of the highly effective ART era
and we felt that differences among highly effective ART
regimens were minor in comparison with differences be-
tween treated and untreated patients. If ART regimens
have improved substantially, our approach will underesti-
mate the effect of ART for the target population (assuming
newer regimens are more efficacious with less potential for
toxicity). We believe measurement error is unlikely to have
had a substantive impact on our results. The covariates we
used in our analysis were all collected for clinical purposes
and represent the information available to the physicians
as they were deciding when to initiate treatment; as such,
even if laboratory values did not reflect true biological val-
ues of CD4 cell count or viral load, it was the observed,
mis-measured value that actually influenced treatment and
should have been included in our model. Having IDU as a
risk factor may not be a perfect proxy for current drug use,
but drug use is a fairly stable behaviour33 and ever drug
use may be as or more important than current use. The
Table 3. Effect of three or more antiretroviral medications (ART) on all-cause mortality for: (i) persons enrolled in the Center for
AIDS Research Network of Integrated Clinical Systems (CNICS) during 1998–2012; and (ii) persons diagnosed with HIV in the
USA during 2009–11
5-year
mortality risk %
(95% confidence interval)
Risk difference, %
(95% confidence interval)
Risk ratio
(95% confidence interval)
Hazard ratio
(95% confidence interval)
CNICS sample
Crude
No ART 12.1 (10.0, 14.3) 0. 1. 1.
ART 11.3 (10.4, 12.1) 0.9 (3.2, 1.5) 0.93 (0.76, 1.13) 1.01 (0.87, 1.17)
Weighted
No ART 28.3 (19.1, 37.5) 0. 1. 1.
ART 10.6 (9.3, 11.9) 17.7 (27.0, 8.4) 0.37 (0.26, 0.53) 0.33 (0.25, 0.43)
HIV-diagnosed, USA
No ART 29.5 (18.2, 40.8) 0. 1. 1.
ART 10.4 (9.2, 11.6) 19.1 (30.5, 7.8) 0.35 (0.23, 0.53) 0.32 (0.23, 0.45)
All estimates were adjusted for: race/ethnicity; sex; age at engagement in care; calendar year of engagement in care; CD4 cell count and viral load most proxim-
ate to CNICS enrolment; history of injection drug use; history of male-to-male sexual contact; study site; and time-varying CD4 cell count, viral load, AIDS diag-
nosis and hepatitis C virus infection. Estimates for persons newly diagnosed with HIV in the USA were further standardized to the distribution of sex, age group,
race/ethnicity, male-to-male sexual contact, injection drug use and AIDS at baseline in the target population.
Table 4. Sensitivity analysis examining hazard ratios for three or more antiretroviral medications (ART) on all-cause mortality
among persons diagnosed with HIV in the USA during 2009–11 (target population), assuming different distributions of CD4 cell
count and viral load in the target (unmeasured) as compared with the CNICS study sample
CD4 cell count in target is on average: Viral load in the target is on average:
10 000 lower than the sample
for patients with a predicted
viral load>100 000
Equal to sample 10 000 higher than the sample
200 cells/ml higher than the sample 0.45 (0.28, 0.71) 0.38 (0.23, 0.63) 0.40 (0.25, 0.65)
100 cells/ml higher than the sample 0.40 (0.27, 0.60) 0.35 (0.24, 0.50) 0.35 (0.24, 0.53)
50 cells/ml higher than the sample 0.37 (0.25, 0.55) 0.35 (0.25, 0.49) 0.34 (0.23, 0.49)
Equal to sample 0.35 (0.24, 0.52) 0.34 (0.24, 0.47) 0.32 (0.22, 0.46)
50 cells/ml lower than the sample 0.33 (0.23, 0.48) 0.32 (0.23, 0.45) 0.30 (0.21, 0.43)
100 cells/ml lower than the sample 0.31 (0.22, 0.45) 0.30 (0.21, 0.42) 0.29 (0.20, 0.41)
200 cells/ml lower than the sample 0.34 (0.23, 0.50) 0.33 (0.22, 0.50) 0.32 (0.21, 0.47)
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date of ART initiation is a critical clinical milestone and
we think it is likely to have been recorded with little error.
Finally, deaths were actively ascertained through clinic
sources and by matching with the Social Security Death
Index. It is therefore unlikely that we have so misclassified
vital status on a sufficient number of patients that it would
have madee a difference in our final estimates.
We estimated the effect of ART under the interventions,
initiating ART immediately or delaying ART initiation at
least 5 years. Given that many HIV-infected persons ex-
perience at least some delay linking to care following HIV
diagnosis,34,35 delayed ART initiation might not be a com-
pletely unrealistic counterfactual exposure distribution for
this target population. Even if the average newly HIV-
diagnosed individual does not delay ART initiation a full 5
years, a substantively interesting risk difference could be
read off the cumulative incidence curves in Figure 1; for
example, at 8 months of follow-up, the median time
between HIV diagnosis and entry to care among a cohort
of newly HIV-diagnosed persons in Philadelphia,34 the risk
difference comparing ART initiated with uninitiated was
approximately 3%. Future work (e.g. using the parametric
g-formula36 or alternative weighting strategies) could pro-
vide generalized impact estimates37 that also account for
treatment heterogeneity and the distribution of covariates
in the target population (note here, that ‘generalized’
implies estimating effects of contrasts other than always
treated versus never treated).
We were interested in estimating the effect of ART on
all-cause mortality among recently HIV-diagnosed persons
in the USA. For an estimate from a study sample to directly
generalize to a specific target population in expectation, a
sufficient set of assumptions include: (i) the study sample is
a random sample of the target population or covariates
associated with selection into the study sample are not also
associated with the outcome;10,38 (ii) no interference;39
and (iii) similar versions of treatment or treatment vari-
ation irrelevance.11 A more detailed discussion of sufficient
assumptions for generalizability appears in the Appendix
(available as Supplementary data at IJE online). We believe
the latter two assumptions to be plausible. We are aware
of no evidence that one person’s ART initiation would af-
fect another (already infected) person’s mortality risk.
Additionally, CNICS patients receive a standard of care
that would be expected to be fairly similar to care provided
by non-CNICS clinics, including the levels of adherence
counselling and supportive services. It is potential viola-
tions of the first assumption that we have addressed in this
analysis. The CNICS cohort is similar to our target popula-
tion on many structural factors, including the health care
delivery system and social context. However, CNICS pa-
tients’ characteristics are not identical to the characteristics
of persons in our target population. We do not, as yet,
have a good understanding of the degree to which non-rep-
resentativeness and non-significant departures from effect
homogeneity across multiple subgroups may interact to
produce changes in the final standardized estimate for the
target population. Therefore, rather than relegating consid-
erations of external validity of our results to a thought ex-
ercise in the discussion of this manuscript, we apply a
formal correction for non-random sampling into the study
sample (inverse probability of sampling weights). Our for-
mal assessment of generalizability provides confidence in
the generalizability of research in the CNICS that uses
mortality as an outcome.
When generalizing our estimate, we may not have con-
trolled for all causes of selection and of the outcome. CD4
cell count and viral load at baseline were associated with
the risk of all-cause mortality, but neither were available in
the national surveillance data for all persons at the time
they were HIV-diagnosed. There is some evidence to sug-
gest that the average baseline CD4 is probably slightly
higher in the target population than in the CNICS. Among
a non-random subset of persons newly diagnosed with
HIV who had a CD4 cell count measured within 3 months,
the proportion with a CD4 cell count 500 cells/ll was
29%, whereas the proportion with a CD4 cell count<200
cells/ll was 33%;14 in the CNICS, those proportions were
24% and 36%, respectively. Failing to account for differ-
ences in the distribution of CD4 cell count and viral load
at baseline between the CNICS and target population may
be a source of residual bias in our generalized effect esti-
mate.47 However, sensitivity analyses indicated that even
moderate shifts in the average CD4 or viral load of patients
in the target population as compared with CNICS failed to
appreciably alter the estimated effect of ART. Treatment
versions may differ between the CNICS and the target
population, as CNICS patients are all treated in academic
medical centres, which may influence patient adherence
and quality of care.41 There was a positive probability of
inclusion in the CNICS in nearly all strata of covariates,
owing to the diversity of the CNICS cohort, which was re-
flected in the stability of the inverse probability of sam-
pling weights. Finally, generalizability may be threatened
in the presence of interference;39 however, interference is
likely negligible for this exposure-outcome relationship.
In this study, we showed that ART reduces mortality in a
cohort that is geographically and clinically representative of
persons recently diagnosed with HIV in the USA. The esti-
mates obtained in the cohort and in our generalization to
the target population of recently HIV-diagnosed persons in
the USA were similar. Furthermore, by including persons
with previous AIDS diagnosis at baseline, and by excluding
people with previous exposure to dual- or monotherapy, we
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have estimated an effect that is pertinent to current stand-
ards of clinical care. Although we observed heterogeneity in
the effect of ART across sub-populations, and differences in
the distribution of those sub-populations between the
CNICS and the target population, this heterogeneity did not
change the overall estimate of the effect of ART among per-
sons recently diagnosed with HIV in the USA.
Supplementary Data
Supplementary data are available at IJE online.
Acknowledgements
The authors would like to thank the patients, principal investigators,
co-investigators and research staff at participating Centers for AIDS
Research Network of Integrated Clinical Studies sites.
Funding
The CNICS is supported by R24 AI067039. C.L., S.R.C. and DW
were supported in part by National Institute of Health grant R01
AI100654. D.W. was also supported in part by National Institute of
Health grant DP2 HD084070. S.R.C., D.W. and J.J.E. were sup-
ported in part by the University of North Carolina at Chapel Hill
Center for AIDS Research (CFAR) and by NIH-funded program
P30 AI50410. M.J.M. was supported in part by National Institute
of Health grant R01 AI103661. The content of this manuscript is
solely the responsibility of the authors and does not necessarily rep-
resent the official views of the National Institutes of Health.
Conflict of interest: M.J.M. reports grants and personal fees from
BMS, personal fees from Gilead, personal fees from Merck
Foundation, grants from Pfizer and grants from Definicare, outside
the submitted work; J.E. reports grants from National Institute of
Health during the conduct of the study, grants and personal fees
from Merck & Co., grants and personal fees from Bristol-Myers
Squibb, grants and personal fees from GlaxoSmithKline/ViiV, per-
sonal fees from Gilead, personal fees from Janssen and personal fees
from Abbvie, outside the submitted work. C.L. reports personal fees
from Gilead outside the submitted work. D.W. engages in occa-
sional ad hoc consulting on epidemiological methods with NIH/
NICHD, outside the submitted work. No other authors have any-
thing to declare.
References
1. HIV-CAUSAL Collaboration; Ray M, Logan R, Sterne JA et al.
The effect of combined antiretroviral therapy on the overall mor-
tality of HIV-infected individuals. AIDS 2010;24:123–37.
2. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of
two nucleoside analogues plus indinavir in persons with human
immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. AIDS Clinical Trials Group 320 Study
Team.NEngl J Med 1997;337:725–33.
3. Cameron DW, Heath-Chiozzi M, Danner S et al. Randomised pla-
cebo-controlled trial of ritonavir in advanced HIV-1 disease. The
Advanced HIV Disease Ritonavir Study Group. Lancet
1998;351:543–49.
4. Walensky RP, Paltiel AD, Losina E et al. The survival benefits of
AIDS treatment in the USA. J Infect Dis 2006;194:11–19.
5. Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 in-
fection with early antiretroviral therapy. N Engl J Med
2011;365:493–505.
6. Gandhi M, Ameli N, Bacchetti P et al. Eligibility criteria for HIV
clinical trials and generalizability of results: the gap between
published reports and study protocols. AIDS 2005;19:1885–96.
7. Weiss NS, Koepsell TD, Psaty BM. Generalizability of the results
of randomized trials. Arch InternMed 2008;168:133–35.
8. Bareinboim E, Pearl J. A general algorithm for deciding trans-
portability of experimental results. Journal of Causal Inference
2013;1:107–34.
9. Cole SR, Stuart EA. Generalizing evidence from randomized
clinical trials to target populations: The ACTG 320 trial. Am J
Epidemiol 2010;172:107–15.
10. Stuart EA, Cole SR, Bradshaw CP, Leaf PJ. The use of propensity
scores to assess the generalizability of results from randomized
trials. J R Stat Soc A 2011;174:369–86.
11. Hernan MA, VanderWeele TJ. Compound treatments and trans-
portability of causal inference. Epidemiology 2011;22:368–77.
12. Sterne JA, Hernan MA, Ledergerber B et al. Long-term effective-
ness of potent antiretroviral therapy in preventing AIDS and
death: a prospective cohort study. Lancet 2005;366:378–84.
13. Cole SR, Hernan MA, Robins JM et al. Effect of highly active
antiretroviral therapy on time to acquired immunodeficiency
syndrome or death using marginal structural models. Am J
Epidemiol 2003;158:687–94.
14. Centers for Disease Control and Prevention. Monitoring Selected
National HIV Prevention and Care Objectives by Using HIV
Surveillance Data – USA and Six Dependent Areas– 2012. HIV
Surveillance Supplemental Report. Dekalb County, GA: Centers
for Disease Control and Prevention, 2014.
15. Kitahata MM, Rodriguez B, Haubrich R et al. Cohort Profile:
The Centers for AIDS Research Network of Integrated Clinical
Systems. Int J Epidemiol 2008;37:948–55.
16. Centers for Disease Control and Prevention. HIV Surveillance
Report, 2011. Dekalb County, GA: Centers for Disease Control
and Prevention, 2013.
17. Cain LE, Robins JM, Lanoy E, Logan R, Costagliola D, Hernan
MA. When to start treatment? A systematic approach to the
comparison of dynamic regimes using observational data. Int J
Biostat 2010;6:Article 18.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Assoc 1958;53:457–81.
19. Efron B. The efficiency of Cox’s likelihood function for censored
data. J Am Stat Assoc 1977;72:557–65.
20. Cole SR, Hernan MA. Constructing Inverse Probability Weights
for Marginal Structural Models. Am J Epidemiol
2008;168:656–64.
21. Cole SR, Hernan MA. Adjusted survival curves with inverse prob-
ability weights. Comput Methods Programs Biomed 2004;75:45–
49.
22. Robins JM, Finkelstein DM. Correcting for noncompliance and
dependent censoring in an AIDS Clinical Trial with inverse prob-
ability of censoring weighted (IPCW) log-rank tests. Biometrics
2000;56:779–88.
23. Centers for Disease Control and Prevention. 1993 revised classi-
fication system for HIV infection and expanded surveillance case
International Journal of Epidemiology, 2016, Vol. 45, No. 1 149
definition for AIDS among adolescents and adults. JAMA
1993;269:729–30.
24. Centers for Disease Control and Prevention. Revised surveillance
case definition for HIV infection – USA, 2014. MMWR
2014;63:1–10.
25. Howe CJ, Cole SR, Westreich DJ, Greenland S, Napravnik S,
Eron JJ Jr. Splines for trend analysis and continuous confounder
control. Epidemiology 2011;22:874–75.
26. Buchanan AL, Hudgens MG, Cole SR et al. Generalizing
Evidence from Randomized Trials using Inverse Probability of
Sampling Weights. Technical Report Series 2015.
27. Efron B, Tibshirani R. An Introduction to the Bootstrap. New
York, NY: Chapman & Hall, 1993.
28. Hernan MA. The hazards of hazard ratios. Epidemiology
2010;21:13–15.
29. Greenland S. Interpretation and choice of effect measures in epi-
demiologic analyses. Am J Epidemiol 1987;125:761–68.
30. Poole C. On the origin of risk relativism. Epidemiology
2010;21:3–9.
31. Grabar S, Lanoy E, Allavena C et al. Causes of the first AIDS-
defining illness and subsequent survival before and after the
advent of combined antiretroviral therapy. HIV Med 2008;9:
246–56.
32. Thompson MA, Aberg JA, Hoy JF et al. Antiretroviral treatment
of adult HIV infection: 2012 recommendations of the
International Antiviral Society-USA panel. JAMA 2012;308:
387–402.
33. Genberg BL, Gange SJ, Go VF, Celentano DD, Kirk GD,
Mehta SH. Trajectories of injection drug use over 20 years
(1988-2008) in Baltimore, Maryland. Am J Epidemiol 2011;
173:829–36.
34. Bamford LP, Ehrenkranz PD, Eberhart MG, Shpaner M, Brady
KA. Factors associated with delayed entry into primary HIV
medical care after HIV diagnosis.AIDS 2010;24:928–30.
35. Torian LV, Wiewel EW, Liu KL, Sackoff JE, Frieden TR. Risk
factors for delayed initiation of medical care after diagnosis of
human immunodeficiency virus. Arch Intern Med 2008;168:
1181–87.
36. Westreich D, Cole SR, Young JG et al. The parametric g-formula
to estimate the effect of highly active antiretroviral therapy on
incident AIDS or death. Stat Med 2012;31:2000–09.
37. Westreich D. From exposures to population interventions:
pregnancy and response to HIV therapy. Am J Epidemiol
2014;179:797–806.
38. Tipton E. Improving Generalizations From Experiments Using
Propensity Score Subclassification: Assumptions, Properties, and
Contexts. J Educ Behav Stat 2013;38:239–66.
39. Hudgens MG, Halloran ME. Toward Causal Inference With
Interference. J Am Stat Assoc 2008;103:832–42.
40. Weisberg HI, Hayden VC, Pontes VP. Selection criteria and gen-
eralizability within the counterfactual framework: explaining
the paradox of antidepressant-induced suicidality? Clin Trials
2009;6:109–18.
41. Frangakis C. The calibration of treatment effects from clinical
trials to target populations. Clin Trials 2009;6:136–40.
42. Greenhouse JB, Kaizar EE, Kelleher K, Seltman H, Gardner W.
Generalizing from clinical trial data: a case study. The risk of sui-
cidality among pediatric antidepressant users. Stat Med 2008;27:
1801–13.
43. Hernan MA, Robins JM. Estimating causal effects from epi-
demiological data. J Epidemiol Community Health 2006;60:
578–86.
44. Westreich D, Cole SR. Invited commentary: positivity in prac-
tice. Am J Epidemiol 2010;171:674–77; discussion 78–81.
45. VanderWeele TJ. Concerning the consistency assumption in
causal inference. Epidemiology 2009;20:880–83.
46. Hernan MA, Cole SR. Invited Commentary: Causal diagrams
and measurement bias. Am J Epidemiol 2009;170:959–62; dis-
cussion 63–64.
47. Robins J, Hernan MA, Brumback B. Marginal Structural Models
and Causal Inference in Epidemiology. Epidemiology 2000;11:
550–60.
150 International Journal of Epidemiology, 2016, Vol. 45, No. 1
